ESPR
MaterialsEsperion Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving ESPR Today?
No stock-specific AI insight has been generated for ESPR yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
ESPR News
20 articles- ARCHIMED to acquire Esperion Therapeutics in $1.1 billion dealQz·May 1, 2026
- Summit’s ‘self-inflicted’ stumble; Esperion’s take-private dealBiopharmadive·May 1, 2026
- Esperion to be Acquired by ARCHIMEDYahoo Finance·May 1, 2026
- Esperion to Report First Quarter 2026 Financial Results on May 7Yahoo Finance·Apr 23, 2026
- Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham ConferenceMarketbeat·Apr 13, 2026
- Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?Yahoo Finance·Apr 9, 2026
- Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis TherapeuticsBenzinga·Apr 2, 2026
- Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)GlobeNewswire Inc.·Apr 2, 2026
- Esperion to Participate in 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Mar 31, 2026
- Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026Yahoo Finance·Mar 30, 2026
- Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?Yahoo Finance·Mar 27, 2026
- Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia GuidelinesYahoo Finance·Mar 20, 2026
- Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific SessionYahoo Finance·Mar 17, 2026
- Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of DyslipidemiaYahoo Finance·Mar 16, 2026
- Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at ConferenceMarketbeat·Mar 16, 2026
- Esperion Therapeutics Inc (ESPR) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...Yahoo Finance·Mar 10, 2026
- Esperion Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 10, 2026
- Esperion Therapeutics (ESPR) Misses Q4 Earnings EstimatesYahoo Finance·Mar 10, 2026
- Esperion Therapeutics: Q4 Earnings SnapshotYahoo Finance·Mar 10, 2026
- Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 10, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Esperion Therapeutics Inc
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.